Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) has been given an average recommendation of “Moderate Buy” by the seven ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.00.

A number of equities analysts recently weighed in on WHWK shares. Wall Street Zen lowered shares of Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Citigroup initiated coverage on shares of Whitehawk Therapeutics in a report on Thursday, April 16th. They issued an “outperform” rating for the company. Citizens Jmp started coverage on shares of Whitehawk Therapeutics in a research note on Thursday, April 16th. They issued a “market outperform” rating and a $8.00 target price on the stock. B. Riley Financial initiated coverage on Whitehawk Therapeutics in a report on Thursday, June 25th. They set a “buy” rating and a $10.00 target price on the stock. Finally, Weiss Ratings lowered Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, June 5th.

Whitehawk Therapeutics Price Performance

NASDAQ WHWK traded down $0.08 during mid-day trading on Tuesday, hitting $3.94. The stock had a trading volume of 240,969 shares, compared to its average volume of 285,334. The firm’s 50 day moving average is $4.29 and its 200 day moving average is $3.56. The stock has a market capitalization of $195.03 million, a price-to-earnings ratio of -2.35 and a beta of 0.77. Whitehawk Therapeutics has a twelve month low of $1.57 and a twelve month high of $5.49.

Whitehawk Therapeutics (NASDAQ:WHWK) last announced its earnings results on Thursday, May 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.04. As a group, equities research analysts expect that Whitehawk Therapeutics will post -1.37 earnings per share for the current year.

Insiders Place Their Bets

In other Whitehawk Therapeutics news, CEO David James Lennon sold 63,945 shares of the company’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $3.40, for a total value of $217,413.00. Following the completion of the sale, the chief executive officer directly owned 533,122 shares in the company, valued at $1,812,614.80. This represents a 10.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Bryan Ball sold 92,460 shares of the firm’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $3.64, for a total value of $336,554.40. Following the completion of the sale, the insider directly owned 397,106 shares of the company’s stock, valued at $1,445,465.84. This trade represents a 18.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 472,490 shares of company stock valued at $1,777,436. Insiders own 49.90% of the company’s stock.

Institutional Investors Weigh In On Whitehawk Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. acquired a new position in Whitehawk Therapeutics in the 3rd quarter valued at about $2,552,000. Dimensional Fund Advisors LP acquired a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth approximately $84,000. Avoro Capital Advisors LLC purchased a new stake in shares of Whitehawk Therapeutics during the 3rd quarter valued at approximately $5,414,000. Suvretta Capital Management LLC purchased a new stake in shares of Whitehawk Therapeutics during the 3rd quarter valued at approximately $7,030,000. Finally, Squarepoint Ops LLC acquired a new position in Whitehawk Therapeutics in the third quarter valued at approximately $159,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.